<DOC>
	<DOCNO>NCT03044080</DOCNO>
	<brief_summary>Clinical randomize clinical trial ass effectiveness walk speed repeat use botulinum neurotoxin type A ( BoNT/A ) post-stroke spastic equinovarus foot three successive infiltration 6-month interval , check sustainability effect great incobotulinumtoxin A ( Xeomin® ) onabotulinumtoxinA ( Botox® ) .</brief_summary>
	<brief_title>Effects Botulinum Neurotoxin Type A ( BoNT/A ) Free Complexing Proteins Spastic Equinovarus Foot</brief_title>
	<detailed_description>Spasticity present 38 % patient six month stroke . Equinovarus foot , without claw toe striatal foot , especially common . There weak moderate evidence favor use botulinum neurotoxin type A ( BoNT/A ) equinovarus foot , stiff-knee pattern may interfere gait ability . Specifically , BoNT/A increase walk speed stroke patient spastic equinovarus foot . Repeated use BoNT/A may lead appearance neutralizing antibody , effect may decrease successive infiltration . Among differential characteristic incobotulinumtoxinA ( Xeomin® ) reduce inactivated botulinum neurotoxin content lack complexing protein , would diminish antigenicity suppose decrease effect successive infiltration . The objective project determine effect walk speed repeat use BoNT/A post-stroke spinal equinovarus foot three consecutive injection 6-month interval investigate whether sustainability effect great incobotulinumtoxinA ( Xeomin® ) onabotulinumtoxinA ( Botox® ) . All patient receive 200-300 unit BoNT/A ( Xeomin ® Botox ® ) distribute accord individual clinical pattern spastic equinovarus foot .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>Clubfoot</mesh_term>
	<mesh_term>Equinus Deformity</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<criteria>Firstever Ischemic haemorrhagic stroke Time since stroke onset : &gt; 6months Hemiparesis equinovarus foot No previous BoNT/A Nonambulant patient Medical contraindication BoNT/A use appear product information sheet</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Walking Disorder</keyword>
	<keyword>Stroke</keyword>
	<keyword>Botulinum Toxin</keyword>
	<keyword>Spasticity</keyword>
</DOC>